作者: D. J. Betteridge
DOI: 10.1007/978-94-009-0729-4_7
关键词: Medicine 、 Coronary heart disease 、 Disease 、 Plasma cholesterol 、 European atherosclerosis society 、 Intensive care medicine
摘要: It is an opportune time to consider the management of hyperlipidaemia. Having accepted that there sufficient evidence attribute a causal role plasma cholesterol in development atherosclerosis-related disease, particularly coronary heart disease (CHD), consensus committees on both sides Atlantic 1,2 have made recommendations with regard optimal lipid and lipoprotein levels (Table 7.1). The British Hyperlipidaemia Association has these guidelines published its own strategies for reducing disease3. Furthermore, study group European Atherosclerosis Society policy statement recognition hyperlipidaemia4.